Information Provided By: 
Fly News Breaks for June 8, 2017
JUNO
Jun 8, 2017 | 07:20 EDT
As noted earlier, BTIG downgraded Juno to Sell from Neutral. Analyst Dane Leone says that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. The analyst expects the revenue generated by Juno's JCAR017 treatment to come in about $1B below consensus expectations through 2026. Target $12.
News For JUNO From the Last 2 Days
There are no results for your query JUNO
